CrowdfundedWealth

NexPoint Capital Q3 2026 10-Q: NAV $3.90 Against a $4.44 8-K, and a Tender Ending Dec 15, 2026

ResearchBy Jorge18 min read8 SEC filings cited

Some links pay us a referral fee; each one says so. Disclosure

Vehicle file: NexPoint Capital, Inc. — assets, distributions, repurchases and every filing, as filed with the SEC.Open the file →

Filing alert · free

An email when NexPoint Capital files with the SEC

An email the day NexPoint Capital files something new, with the link to the document on the SEC site.

Quick answer

NexPoint Capital, Inc. (CIK 1588272), a non-traded business development company in Dallas, filed its Form 10-Q for the quarter ended September 30, 2026 on November 16, 2026 (accession 0001193125-26-462744). Net asset value per share was $3.90 at September 30, 2026, down from $4.55 at June 30, 2026 and $4.39 at December 31, 2025, on net assets of $32,254,150. The same day it opened a new tender for up to 1% of its shares (83,060.308 shares), expiring at 4:00 p.m. New York time on December 15, 2026, at a price of not less than the NAV calculated after that date; the last NAV it cites is $3.79. The quarter's loss came from one holding: the net change in unrealized value was $(4,587,498), which the 10-Q says was “primarily driven by the performance of Sapience Therapeutics, Inc.”, whose preferred shares went from $8.6 million at June 30, 2026 to $4.1 million at September 30, 2026. The 8-K filed on October 13, 2026 had put the NAV at September 30 at $4.44, 14% above the 10-Q figure (our arithmetic). The previous tender, which expired September 22, 2026, paid $4.64 a share.

Key takeaways

  • NAV per share was $3.90 at September 30, 2026 in the 10-Q, against $4.55 at June 30, 2026 (down 14.3%, our arithmetic) and $4.39 at December 31, 2025. Net assets fell from $37,706,737 to $32,254,150 in the quarter, a drop of $5,452,587, of which $4,527,992 was the loss from operations.
  • One company explains the loss. Sapience Therapeutics preferred shares were carried at $8.6 million on June 30, 2026 and $4.1 million on September 30, 2026; the two Sapience lines now stand at $4,091,111 against a cost of $8,080,385 (50.6% of cost, our arithmetic).
  • The new tender: up to 1% of shares, 83,060.308 shares, expiring December 15, 2026 at 4:00 p.m. New York time, at a price of not less than the NAV next calculated after expiration plus unpaid dividends accrued through that date. The offer cites $3.79 as the last adviser-approved NAV; at that price the full 1% would cost about $314,798.57. If requests exceed the 1%, shares are bought pro rata.
  • The September tender was paid at $4.64 per the company's 8-K of September 25, 2026, and the 10-Q's own NAV for September 30 is $3.90, so tendering holders were paid 19.0% more than the reported NAV eight days later (our arithmetic). The next price is the first set after the write-down.
  • Distributions did not move: $0.09 a share, $743,397 for the quarter and $2,239,293 for nine months, against net investment income of $59,506 and $250,900. Our arithmetic: income covered 8.0% of the quarter's distribution and 11.2% of the nine months'. The 10-Q says the tax character of 2026 distributions “will be determined after year-end”.
  • The portfolio is smaller and more concentrated: 17 investments (21 at June 30, 2026), 56.4% common stock, 14.5% first-lien loans, 14.4% an LLC that holds real estate, 14.1% preferred stock, and 88.2% of net assets valued by the adviser rather than from market quotes. 10.2% of fixed-income investments were on non-accrual.
  • The 10-Q puts the count of shares tendered in the September offer at 83,860 and shows 83,860 repurchased; the company's press release gave 83,436.24785, which is almost exactly the 83,436.296-share cap of that offer. The two figures are 424 shares apart and the filings do not reconcile them.

CSV · 105 rows

NexPoint Capital: Q3 2026 10-Q balance sheet, NAV, portfolio, distributions and the November 2026 tender

105 rows from the Q3 2026 10-Q (filed Nov 16, 2026), the Q2 10-Q, the Schedule TO-I and Offer to Purchase of Nov 16, 2026 and the NAV 8-Ks, with the SEC accession on each. Our arithmetic is labelled in the note column.

What the November 16, 2026 filings are

Three documents arrived on the same day. The Form 10-Q covers the quarter ended September 30, 2026. A Form 8-K (accession 0001193125-26-461198) states that “As of November 11, 2026, the net asset value per share and the price at which the Company issues shares under its distribution reinvestment plan (the “DRP”) was determined to be $3.79 per share.” And a Schedule TO-I (accession 0001193125-26-463684) opens the quarterly tender, with the Offer to Purchase dated November 16, 2026 as Exhibit (a)(1)(ii).

The company's offering closed on February 14, 2018 at $10.75 a share, so $3.79 is 64.7% below that price (our arithmetic). Our earlier page on this fund, NexPoint Capital: NAV, the shrinking tender and who owns 30.7%, covers the history from 2014 and the 8-K NAV series; this page reads the 10-Q and the new tender and does not repeat it.

What changed between June 30 and September 30, 2026

ItemJun 30, 2026Sep 30, 2026Change
NAV per share (10-Q)$4.55$3.90down 14.3%
Net assets$37,706,737$32,254,150down $5,452,587
Shares outstanding8,295,9478,259,769down 36,178
Total investments at fair value$38,359,807$32,466,665down $5,893,142
Number of investments2117down 4
Common stock at fair value$15,616,239$18,303,352up $2,687,113
Preferred stock at fair value$11,316,959$4,591,111down $6,725,848
Healthcare share of portfolio37.2%31.0%down 6.2 points
Fixed income on non-accrual75.7%10.2%down 65.5 points
Cash and cash equivalents$616,357$963,593up $347,236
Distributions payable$746,635$743,400down $3,235

Source: Form 10-Q for September 30, 2026 (accession 0001193125-26-462744) and Form 10-Q for June 30, 2026 (accession 0001193125-26-351830). Changes are our arithmetic.

The quarter in net assets: the loss from operations was $4,527,992 ($59,506 of net investment income and a net change in unrealized value of $(4,587,498)); distributions took $743,397; share repurchases took $389,096 and reinvested dividends added $207,898. Those four lines sum to the $5,452,587 fall (our arithmetic). Preferred stock fell by more than the whole portfolio did because common stock rose: the 10-Q lists Apnimed, Inc. as common shares valued at $3.0 million at September 30, 2026 and as preferred shares at $2.2 million at December 31, 2025, and it does not explain the exchange.

The non-accrual line swings widely and the filings do not say why: the June 30 10-Q gave 75.7% of fixed-income investments, the September 10-Q gives 10.2% (December 31, 2025: 9.4%). The schedule lists CCS Medical's $3,000,000 first-lien term loan at an interest rate of 0.00%, with its maturity moved from April 7, 2026 to April 7, 2027, and MidWave Wireless' $1,687,126 loan at 13% paid in kind.

The write-down: Sapience Therapeutics

The 10-Q says the net change in unrealized value in the quarter was “primarily driven by the performance of Sapience Therapeutics, Inc.” Sapience is a clinical-stage drug developer, and the fund holds two series of its preferred shares, all or part of them through a holding company, the schedule's footnote says:

SecuritySharesCostFair value Sep 30, 2026
Sapience Series B Preferred1,111,111$4,080,000$1,711,111
Sapience Series B-1 Preferred1,619,048$4,000,385$2,380,000
Total2,730,159$8,080,385$4,091,111

Source: Consolidated Schedule of Investments, Form 10-Q for September 30, 2026. The totals are our arithmetic. The 10-Q gives the company's aggregate Sapience value as $8.6 million at June 30, 2026 and December 31, 2025 and $4.1 million at September 30, 2026.

The aggregate fall of about $4.5 million (our arithmetic, from the rounded $8.6 million and $4.1 million) is almost the entire $4,587,498 net unrealized loss for the quarter, which the 10-Q puts at $0.55 a share. The filing does not say what happened at Sapience; its value here is a Level 3 estimate set by the Adviser, not a market price.

Three NAVs for September 30, and the price of the next tender

DateNAV per shareWhere it comes from
Jul 31, 2026$4.67Offer to Purchase of Aug 21, 2026
Sep 22, 2026$4.648-K of Sep 25, 2026; the price of the September tender
Sep 30, 2026$4.448-K filed Oct 13, 2026 (adviser's NAV and DRP price)
Sep 30, 2026$3.90Form 10-Q filed Nov 16, 2026 (net assets divided by shares)
Oct 31, 2026$3.79Offer to Purchase of Nov 16, 2026, called the last adviser-approved NAV
Nov 11, 2026$3.798-K filed Nov 16, 2026

Sources: Offers to Purchase of August 21 and November 16, 2026, and Forms 8-K with accessions 0001193125-26-401339, 0001193125-26-420226 and 0001193125-26-461198, and the Form 10-Q.

For the same date, September 30, 2026, the adviser's 8-K and the 10-Q differ by $0.54, which makes the 8-K figure 13.8% higher (our arithmetic). Our earlier page on this fund tracks the same kind of gap at December 31, 2025 and June 30, 2026. This time the 10-Q lands lower, and the next adviser figure, $3.79, is close to it. The offer describes $3.79 as of October 31, 2026, while the 8-K filed with it dates the same figure November 11, 2026. We do not know why two dates are given.

In dollars, 1,000 shares would be worth $4,640 at the September price and $3,790 at $3.79, which is 18.3% less (our arithmetic). The price paid in this offer is the NAV “next calculated following the Expiration Date,” so it can differ from $3.79 in either direction.

The new tender: terms from the Offer to Purchase

TermNovember 2026 offerSeptember 2026 offer
FiledSchedule TO-I, Nov 16, 2026Schedule TO-I, Aug 21, 2026
SizeUp to 1%, 83,060.308 sharesUp to 1%, 83,436.296 shares
Expires4:00 p.m. New York time, Dec 15, 20264:00 p.m. New York time, Sep 22, 2026
PriceNot less than NAV next calculated after expiration, plus unpaid dividends accrued through Dec 15, 2026Same formula, dividends accrued through Sep 22, 2026
Last NAV cited$3.79 (Oct 31, 2026)$4.67 (Jul 31, 2026)
Cost of the full 1% at that NAV$314,798.57not stated in the term sheet
ProrationPro rata if requests exceed the 1%Pro rata if requests exceed the 1%
Minimum balance$2,500 of shares must remain after a partial tender$2,500 of shares must remain after a partial tender

Sources: Offers to Purchase dated November 16, 2026 (accession 0001193125-26-463684) and August 21, 2026 (accession 0001193125-26-360721).

Other terms in the November Offer to Purchase:

  • No minimum tender, and a partial tender needs a floor. The company is not requiring that a holder tender at least 25% of his or her holding, but one who tenders only part must keep shares worth at least $2,500. We found no odd-lot priority in the document.
  • Proration. The Offer says: “If the amount of repurchase requests exceeds the number of Shares the Company seeks to repurchase, Shares will be repurchased on a pro-rata basis.” Our arithmetic: if holders asked for 166,000 shares against the 83,060.308 on offer, each would be bought for about half of the request.
  • Withdrawal. Tendered shares can be withdrawn until the expiration date and, if not yet accepted for payment, for up to 40 business days after it.
  • Paid from reinvested dividends. “The Company will use the proceeds received from the sale of shares of its common stock under the Company’s distribution reinvestment plan to pay for Shares tendered”; cash, borrowings or sales of investments may be used at the Board's discretion. There are no financing conditions.
  • Conditions. The Offer cannot be completed if it would impair the company's treatment as a regulated investment company, break asset-coverage rules if senior securities exist, or if specified legal actions or market closures occur.
  • Fees. Holders pay no commission to the company; a broker may charge one. LODAS Transfer, LLC is the tender agent, and the company pays no fee to anyone else for soliciting tenders. The filing fee on the Schedule TO-I was $27.39 on a transaction value of $314,798.57.
  • Insiders. The Offer says no director or executive officer owns shares, and that the Investment Adviser may take part in the offer. The Board approved the offer on September 10, 2026.
  • What a tender is not. Neither the company, the Board nor the Adviser makes a recommendation on whether to tender. The Offer also warns that a payment may be less than a holder would receive in a liquidity event, which the company says it intends to seek within five years after the offering stage but cannot promise.

The September result: two numbers for one offer

The company's press release of September 25, 2026 says 83,436.24785 shares were tendered in the offer for up to 1% at $4.64. The 10-Q says 83,860 shares were tendered, “constituting approximately 1%,” and the statement of changes in net assets shows 83,860 shares repurchased in the quarter for $389,096, which is $4.64 a share (our arithmetic). The September offer's own cap was 83,436.296 shares, so 83,860 is 424 shares above it (our arithmetic). The 10-Q does not mention proration for September. For the nine months, the fund repurchased 249,632 shares for $1,116,707 and issued 150,057 shares through reinvestment for $663,178, a net shrinkage of 99,575 shares; no shares were repurchased under its death and disability program.

Is the distribution covered?

PeriodNet investment incomeDistributions declaredIncome as % of distributions
Quarter ended Sep 30, 2026$59,506$743,3978.0%
Nine months ended Sep 30, 2026$250,900$2,239,29311.2%
Quarter ended Sep 30, 2025$164,133$759,20821.6%
Nine months ended Sep 30, 2025$673,771$2,295,21129.4%

Source: Form 10-Q for September 30, 2026, Item 2. The percentages are our arithmetic.

The 10-Q says the excess “was funded from cash on hand, and proceeds from sales and principal repayments of investments.” For the full year 2025 it states that $3,047,552, all of the dividends, was classified as a return of capital. For 2026 it says “The tax character of 2026 distributions will be determined after year-end, and a portion may be treated as a return of capital.” The Board declared $0.09 a share on October 13, 2026, payable that day to holders of record on September 30. At the 10-Q's $3.90, the $0.36 annual rate is 9.2% of NAV (our arithmetic), paid at a time when income covers about a tenth of it. Expenses were $1,244,197 for nine months, with $302,695 waived or reimbursed by the Adviser.

What the portfolio looks like now

HoldingTypeFair value Sep 30, 2026Share of net assets
MidWave Wireless, Inc.Common stock$5,602,77217.4%
NexPoint Capital REIT, LLCLLC interests$4,667,54314.5%
Sapience Therapeutics, Inc.Preferred stock$4,091,11112.7%
PlantSwitch, Inc.Common stock$4,063,91912.6%
SK Telecom CS T1 Co., Ltd.Common stock$3,439,96010.7%
CCS Medical, Inc.First-lien term loan$3,000,0009.3%
Apnimed, Inc.Common stock$2,958,9899.2%

Source: Consolidated Schedule of Investments, Form 10-Q for September 30, 2026. The shares of net assets are the filing's percentages for MidWave and the LLC and our arithmetic for the others.

Seven holdings are 86.3% of net assets (our arithmetic), the largest being MidWave Wireless. The 10-Q states that $28,460,327, or 88.2% of net assets, was fair valued by the Adviser. It also lists the fund as an affiliated person of NexPoint Real Estate Finance, Inc., NexPoint Capital REIT, LLC and NexPoint Residential Trust, Inc.; the LLC is the only large one, and the two listed companies are $165,567 and $456,710. Healthcare is 31.0% of the portfolio, against 38.8% at December 31, 2025, although the fund's tender documents describe a healthcare-focused strategy.

Who owns the shares

On September 30, 2026, Liberty CLO Holdco Ltd. held 2,549,002 shares, which the 10-Q puts at 30.9% of the shares outstanding and about $10.0 million. The Offer to Purchase, as of October 31, 2026, shows the same shares as 30.7%. The count has not changed since the Adviser's stake was sold to Liberty in 2023, so the percentage rises whenever the company buys back shares. The Offer lists Liberty as the only holder above 25%.

What a holder can do with this

This page is analysis of public documents, not investment, legal or tax advice.

  • Decide before December 15, 2026, at 4:00 p.m. New York time. If your shares are in a broker's name, the broker may need your instruction earlier; the Offer says to ask it.
  • Know that you will not know the price. It is the NAV calculated after the offer ends. The last figure given is $3.79; the 10-Q number is $3.90; the previous price was $4.64.
  • Expect proration. The three 2026 offers so far each drew requests of about 1%, the size of the offer, so a partial fill is possible. What is not filled stays with you until the next offer.
  • Check the tax. A sale is a taxable event, and a distribution classed as return of capital lowers your cost basis. Our page on return of capital in REIT distributions explains the mechanics, and the census of non-traded BDC tender results shows what other funds did in the same quarter.
  • Compare funds. Our list of non-traded BDCs puts NexPoint Capital's NAV next to the others.

If how much of your savings sits in an illiquid fund that now earns about 8 cents for every dollar it distributes is a large part of your plan, a second opinion may help.

FAQ

All figures are from the filings cited, read on EDGAR on November 17, 2026: Form 10-Q for September 30, 2026 (accession 0001193125-26-462744), Form 10-Q for June 30, 2026 (accession 0001193125-26-351830), Schedule TO-I and Offer to Purchase of November 16, 2026 (accession 0001193125-26-463684), Schedule TO-I of August 21, 2026 (accession 0001193125-26-360721), Schedule TO-I/A of September 28, 2026 (accession 0001193125-26-405214) and Forms 8-K (accessions 0001193125-26-401339, 0001193125-26-420226, 0001193125-26-461198). Percentage changes and totals are our arithmetic. This is analysis of public documents, not investment, legal or tax advice.

Affiliate Disclosure: Some links are affiliate links. We may earn a commission at no extra cost to you. This does not affect our ratings. Learn more.